Myocardial Infarction Market Report 2026

Myocardial Infarction Market Overview

• Myocardial Infarction market size has reached to $2.19 billion in 2025 • Expected to grow to $3.15 billion in 2030 at a compound annual growth rate (CAGR) of 7.5% • Growth Driver: Rising Incidence Of Cardiovascular Diseases Is Anticipated To Fuel The Myocardial Infarction Market • Market Trend: Novel Drugs For Targeted Cardiovascular Inflammation Treatment • North America was the largest region in 2025 and Europe is the fastest growing region.

What Is Covered Under Myocardial Infarction Market?

Myocardial infarction is a potentially fatal disorder that develops when the heart muscle's blood supply is suddenly interrupted, resulting in tissue damage. Myocardial infarction is triggered by high levels of low-density lipoprotein in the blood, high blood pressure, and smoking. The main types of drug classes included in myocardial infarction are antiplatelet agents, glycoprotein IIB/IIIA inhibitors, antithrombotic agents, beta-adrenergic blockers, vasodilators, angiotensin-converting enzyme (ACE) inhibitors, angiotensin-receptor blockers, analgesics, and thrombolytics. Antiplatelet agents refer to drugs that lessen the body's capacity to produce blood clots by preventing platelets from clumping together. These can be administered through oral and injectable routes and are sold through several distribution channels, such as hospital pharmacies, retail pharmacies, and online pharmacies.

What Is The Myocardial Infarction Market Growth Forecast?

The myocardial infarction market size is expected to see strong growth in the next few years. It will grow to $3.15 billion in 2030 at a compound annual growth rate (CAGR) of 7.5%. The growth in the forecast period can be attributed to advancement in cardiac drug formulations, growing adoption of telecardiology, rising investment in cardiology r&d, increasing use of ai for cardiac diagnosis, expansion of emergency cardiac care infrastructure. Major trends in the forecast period include increasing adoption of advanced cardiac rehabilitation programs, growing use of combination drug therapies for post-mi care, rising emphasis on early detection and prevention of heart attacks, expanding use of minimally invasive procedures in acute mi management, increasing focus on lifestyle modification and long-term risk reduction.

Global Myocardial Infarction Market Segmentation

1) By Drug Class: Antiplatelet Agents, Glycoprotein IIb Or IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers, Vasodilators, Angiotensin-Converting Enzyme (ACE) Inhibitors, Angiotensin-Receptor Blockers, Analgesics, Thrombolytics 2) By Route Of Administration: Oral, Injectable 3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies Subsegments: 1) By Antiplatelet Agents: Aspirin, Clopidogrel, Ticagrelor 2) By Glycoprotein IIb Or IIIa Inhibitors: Abciximab, Eptifibatide, Tirofiban 3) By Antithrombotic Agents: Heparins, Direct Oral Anticoagulants (DOACs) 4) By Beta-Adrenergic Blockers: Metoprolol, Carvedilol 5) By Vasodilators: Nitroglycerin, Isosorbide Dinitrate 6) By Angiotensin-Converting Enzyme (ACE) Inhibitors: Lisinopril, Enalapril 7) By Angiotensin-Receptor Blockers: Losartan, Valsartan 8) By Analgesics: Morphine, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) 9) By Thrombolytics: Alteplase, Reteplase

What Is The Driver Of The Myocardial Infarction Market?

The rising incidence of cardiovascular diseases is expected to propel the growth of the myocardial infarction market going forward. Cardiovascular diseases refer to a class of disorders affecting the heart and blood vessels. Myocardial infarction drug classes are employed to manage and treat cardiovascular diseases, particularly addressing the aftermath of heart attacks. For instance, in September 2024, according to the data published by the British Heart Foundation, a UK-based cardiovascular research charity, in the UK, approximately 7.6 million people are affected by heart and circulatory diseases, with around 4 million males and 3.6 million females living with these conditions. These diseases are responsible for about 27% of all deaths in the UK, translating to over 170,000 deaths annually, or roughly 480 deaths each day, equating to one death every three minutes. Therefore, the rising incidence of cardiovascular diseases is driving the myocardial infarction industry.

Key Players In The Global Myocardial Infarction Market

Major companies operating in the myocardial infarction market are Pfizer Inc, Johnson & Johnson Services Inc, Bayer AG, Novartis AG, Sanofi SA, Bristol Myers Squibb Company, AstraZeneca PLC, Boehringer Ingelheim GmbH, Daiichi Sankyo Co Ltd, Apotex Inc, Par Pharmaceutical Companies Inc, Amgen Inc, Merck & Co Inc, Takeda Pharmaceutical Company Ltd, Gilead Sciences Inc, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd, Sun Pharmaceutical Industries Ltd, Dr Reddy’s Laboratories Ltd, Lupin Ltd, United Therapeutics Corporation, CSPC Pharmaceutical Group Ltd, Zhejiang Huahai Pharmaceutical Co Ltd, Qilu Pharmaceutical Co Ltd, Chia Tai Tianqing Pharmaceutical Group Co Ltd.

Global Myocardial Infarction Market Trends and Insights

Major companies in the myocardial infarction market are focused on developing novel drugs, such as anti-inflammatory drugs, for targeted cardiovascular inflammation treatment and to gain a competitive edge in the market. Anti-inflammatory drugs are medications that reduce inflammation, alleviating pain and swelling by targeting the body's immune response. For instance, in June 2023, Agepha Pharma, a Slovakia-based manufacturer of medical products, received FDA approval for its developed drug, Lodoco (colchicine), the first anti-inflammatory drug to target the underlying cause of atherosclerotic cardiovascular disease. Lodoco aims to reduce the risk of myocardial infarction, stroke, coronary revascularization, and cardiovascular death in adult patients. It can be used alone or with cholesterol-lowering medications. Lodoco, a reformulated low-dose colchicine, demonstrated a 31% reduction in the overall risk of cardiovascular death, myocardial infarction, stroke, or coronary revascularization in a clinical trial.

What Are Latest Mergers And Acquisitions In The Myocardial Infarction Market?

In March 2024, Novo Nordisk, a Denmark-based provider of therapies for diabetes and cardiovascular conditions, acquired Cardior Pharmaceuticals for approximately €1.025 billion ($1.11 billion). With this acquisition, Novo Nordisk aims to strengthen its cardiovascular disease portfolio by adding advanced RNA-targeting therapeutics and accelerating the development of a first-in-class therapy for post-myocardial-infarction heart failure. Cardior Pharmaceuticals is a Germany-based biotechnology company developing RNA-based therapeutics, including its lead microRNA-targeting candidate CDR132L for heart failure following myocardial infarction.

Regional Outlook

North America was the largest region in the myocardial infarction market in 2025. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Myocardial Infarction Market?

The myocardial infarction market consists of sales of heparin, bivalirudin, and enoxaparin. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Myocardial Infarction Market Report 2026?

The myocardial infarction market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the myocardial infarction industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.